,i  #aaith ,,congress  #ast ,session    
,h4 ,r4 #ccge  ,,in ,,the ,,house ,,of  
,,representatives  ,may #ac1 #bjbe,mr4  
,van ,drew introduced the following     
bill2 which was referred to the         
,committee on ,energy and ,commerce  ,a 
,,bill  ,to require that the retail list
 price for certain prescription drugs   
and biological products may not exceed  
the average retail list price for the   
drug or biological product among certain
 nations4  #a4 ,short title ,this ,act  
may be cited as the ,fair ,prescription 
,drug ,prices for ,americans ,act4  #b4 
,international reference pricing for    
prescription drugs and biological       
products  7a7 ,definitions ,in this     
section3  7#a7 ,biological product ,the 
term biological product means a         
biological product licensed under       
subsection 7a7 or 7k7 of section #cea of
 the ,public ,health ,service ,act 7#db 
,u4,s4,c4 #bfb74  7#b7 ,drug ,the term  
drug means a drug approved under        
subsection 7c7 or 7j7 of section #eje of

 the ,federal ,food1 ,drug1 and         
,cosmetic ,act 7#ba ,u4,s4,c4 #cee74    
7#c7 ,secretary ,the term ,secretary    
means the ,secretary of ,health and     
,human ,services4  7b7 ,cap on retail   
list price of prescription drugs and    
biological products ,the retail list    
price in the ,united ,states for a drug 
or a biological product may not exceed  
the average retail list price for the   
drug or biological product among        
,canada1 ,france1 ,germany1 ,italy1     
,japan1 and the ,united ,kingdom1 as    
calculated under subsection 7c74  7c7   
,calculation of average retail list     
price ,the ,secretary shall calculate on
 an annual basis the average retail list
 price for each drug and biological     
product sold in ,canada1 ,france1       
,germany1 ,italy1 ,japan1 and the       
,united ,kingdom1 through a combination 
of data reported by manufacturers of    
drugs and biological products under     
subsection 7e7 and data obtained through
 review of publicly filed materials by  

manufacturers of drugs and biological   
products in such countries4  7d7 ,civil 
monetary penalty  7#a7 ,in general ,any 
manufacturer that violates subsection   
7b7 with respect to a drug or biological
 product shall be subject to a civil    
monetary penalty imposed by the         
,secretary in amount equal to the       
product obtained by multiplying--  7,a7 
the difference between-- 7i7 the list   
price for the drug or biological product
 sold in the ,united ,states2 and  7ii7 
the average retail list price for the   
drug or biological product sold in      
,canada1 ,france1 ,germany1 ,italy1     
,japan1 and the ,united ,kingdom1 as    
calculated under subsection 7c72 and    
7,b7 #aj4  7#b7 ,requirement ,the amount
 of a civil monetary penalty under      
paragraph 7#a7 shall be calculated and  
charged for each unit of drug or        
biological product sold4  7e7 ,data     
collection ,each manufacturer of a drug 
or biological product shall submit to   
the ,secretary on an annual basis--     

7#a7 the list price for the drug or     
biological product sold in the ,united  
,states2 and  7#b7 the list price for   
the drug or biological product sold in  
each of ,canada1 ,france1 ,germany1     
,italy1 ,japan1 and the ,united         
,kingdom4  7f7 ,guidance and regulations
 ,the ,secretary shall issue guidance   
and promulgate regulations to implement 
this section4